LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BT-20 | Radicicol | 3.33 | uM | LJP6 | 1 | K08 | 72 | hr | 1097 | 977 | 3769 | 0.2592 | -0.0450 |
BT-20 | Radicicol | 3.33 | uM | LJP6 | 2 | K08 | 72 | hr | 1097 | 978 | 3769 | 0.2595 | -0.0446 |
BT-20 | Radicicol | 3.33 | uM | LJP6 | 3 | K08 | 72 | hr | 1097 | 1068 | 3769 | 0.2833 | -0.0109 |
BT-20 | Seliciclib | 3.33 | uM | LJP5 | 1 | J02 | 72 | hr | 1097 | 2731 | 3769 | 0.7245 | 0.6114 |
BT-20 | Seliciclib | 3.33 | uM | LJP5 | 2 | J02 | 72 | hr | 1097 | 3060 | 3769 | 0.8118 | 0.7345 |
BT-20 | Seliciclib | 3.33 | uM | LJP5 | 3 | J02 | 72 | hr | 1097 | 2711 | 3769 | 0.7192 | 0.6039 |
BT-20 | Ruxolitinib | 3.33 | uM | LJP5 | 1 | O14 | 72 | hr | 1097 | 3916 | 3769 | 1.0389 | 1.0548 |
BT-20 | Ruxolitinib | 3.33 | uM | LJP5 | 2 | O14 | 72 | hr | 1097 | 3908 | 3769 | 1.0367 | 1.0518 |
BT-20 | Ruxolitinib | 3.33 | uM | LJP5 | 3 | O14 | 72 | hr | 1097 | 3747 | 3769 | 0.9940 | 0.9916 |
BT-20 | XL147 | 3.33 | uM | LJP5 | 1 | G08 | 72 | hr | 1097 | 3139 | 3769 | 0.8327 | 0.7641 |
BT-20 | XL147 | 3.33 | uM | LJP5 | 2 | G08 | 72 | hr | 1097 | 3495 | 3769 | 0.9272 | 0.8973 |
BT-20 | XL147 | 3.33 | uM | LJP5 | 3 | G08 | 72 | hr | 1097 | 3321 | 3769 | 0.8810 | 0.8322 |
BT-20 | Saracatinib | 3.33 | uM | LJP6 | 1 | D08 | 72 | hr | 1097 | 2154 | 3769 | 0.5714 | 0.3955 |
BT-20 | Saracatinib | 3.33 | uM | LJP6 | 2 | D08 | 72 | hr | 1097 | 2619 | 3769 | 0.6948 | 0.5695 |
BT-20 | Saracatinib | 3.33 | uM | LJP6 | 3 | D08 | 72 | hr | 1097 | 2242 | 3769 | 0.5948 | 0.4284 |
BT-20 | Selumetinib | 3.33 | uM | LJP6 | 1 | M08 | 72 | hr | 1097 | 3243 | 3769 | 0.8603 | 0.8030 |
BT-20 | Selumetinib | 3.33 | uM | LJP6 | 2 | M08 | 72 | hr | 1097 | 3301 | 3769 | 0.8757 | 0.8247 |
BT-20 | Selumetinib | 3.33 | uM | LJP6 | 3 | M08 | 72 | hr | 1097 | 3538 | 3769 | 0.9386 | 0.9134 |
BT-20 | Sirolimus | 3.33 | uM | LJP6 | 1 | L14 | 72 | hr | 1097 | 2361 | 3769 | 0.6263 | 0.4729 |
BT-20 | Sirolimus | 3.33 | uM | LJP6 | 2 | L14 | 72 | hr | 1097 | 2284 | 3769 | 0.6059 | 0.4441 |
BT-20 | Sirolimus | 3.33 | uM | LJP6 | 3 | L14 | 72 | hr | 1097 | 2285 | 3769 | 0.6062 | 0.4445 |
BT-20 | Sorafenib | 3.33 | uM | LJP6 | 1 | B08 | 72 | hr | 1097 | 3211 | 3769 | 0.8518 | 0.7910 |
BT-20 | Sorafenib | 3.33 | uM | LJP6 | 2 | B08 | 72 | hr | 1097 | 3037 | 3769 | 0.8057 | 0.7259 |
BT-20 | Sorafenib | 3.33 | uM | LJP6 | 3 | B08 | 72 | hr | 1097 | 3084 | 3769 | 0.8181 | 0.7435 |
BT-20 | SU11274 | 3.33 | uM | LJP5 | 1 | J08 | 72 | hr | 1097 | 3414 | 3769 | 0.9057 | 0.8670 |